Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19.
Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19.
复制标题
DOI：
10.1038/s41598-021-85809-y
复制
发表时间：
2021-03-18
影响因子：
4.6
通讯作者：
Budhiraja S
中科院分区：
文献类型：
--
作者：
Jevalikar G;Mithal A;Singh A;Sharma R;Farooqui KJ;Mahendru S;Dewan A;Budhiraja S
由于其免疫调节作用，维生素D缺乏症（VDD）被认为会影响COVID-19的结果。我们对因COVID-19住院的患者进行了一项前瞻性观察性研究。血清25-OHD水平< 20 ng/mL被认为是VDD。根据WHO临床改善顺序量表（OSCI）将患者分为轻度和重度疾病。在招募的410例患者中，VDD患者（197，48.2%）明显年轻，合并症较少。VDD组的PTH水平显著较高（63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL）。VDD组与非VDD组的重症病例比例（13.2%vs.14.6%）、死亡率（2%vs.5.2%）、需氧量（34.5%vs.43.4%）、ICU入院率（14.7%vs.19.8%）差异均无统计学意义。血清25-OHD水平与所研究的炎症标志物之间无显著相关性。血清甲状旁腺素水平与D-二聚体（r 0.117，p- 0.019）、铁蛋白（r 0.132，p-0.010）和LDH（r 0.124，p-0.018）相关。在VDD患者中，128例（64.9%）接受口服胆钙化醇治疗（中位剂量为60，000 IU）。治疗组与未治疗组的重症病例、吸氧或ICU入院比例无显著差异。总之，入院时的血清25-OHD水平与住院COVID-19患者的炎症标志物、临床结局或死亡率无关。用胆钙化醇治疗VDD对结局没有任何影响。
Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.
登录
查看更多内容
影响因子：
3.7
作者：
Maghbooli Z;Sahraian MA;Ebrahimi M;Pazoki M;Kafan S;Tabriz HM;Hadadi A;Montazeri M;Nasiri M;Shirvani A;Holick MF
通讯作者：
Holick MF
影响因子：
5.9
作者：
Radujkovic A;Hippchen T;Tiwari-Heckler S;Dreher S;Boxberger M;Merle U
通讯作者：
Merle U
影响因子：
56.9
作者：
Liu, PT;Stenger, S;Modlin, RL
通讯作者：
Modlin, RL
影响因子：
39
作者：
Wu, Chaomin;Chen, Xiaoyan;Song, Yuanlin
通讯作者：
Song, Yuanlin
DOI：
10.1136/bmj.i6583
发表时间：
2017-02-15
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Martineau AR;Jolliffe DA;Hooper RL;Greenberg L;Aloia JF;Bergman P;Dubnov-Raz G;Esposito S;Ganmaa D;Ginde AA;Goodall EC;Grant CC;Griffiths CJ;Janssens W;Laaksi I;Manaseki-Holland S;Mauger D;Murdoch DR;Neale R;Rees JR;Simpson S Jr;Stelmach I;Kumar GT;Urashima M;Camargo CA Jr
通讯作者：
Camargo CA Jr